What is Vida Diagnostics?
VIDA Diagnostics is at the forefront of revolutionizing lung and respiratory care. The company empowers healthcare organizations and physicians by providing a comprehensive approach that integrates proven quality and clinical leadership. Through advanced quantitative data intelligence and compelling visualizations, VIDA assists clinicians in managing patients diagnosed with or at risk of chronic obstructive pulmonary disease (COPD), interstitial lung disease (ILD), lung cancer, and COVID-19. This focus on data-driven insights aims to streamline care coordination and drive significant efficiencies in patient management.
How much funding has Vida Diagnostics raised?
Vida Diagnostics has raised a total of $10.1M across 4 funding rounds:
Other Financing Round
$2.5M
Series B
$5.1M
Other Financing Round
$500K
Series C
$2M
Other Financing Round (2014): $2.5M with participation from Next Level Ventures
Series B (2016): $5.1M led by Chartline Capital Management, Iowa Seed Fund, Rittenhouse Ventures, and Next Level Ventures
Other Financing Round (2019): $500K supported by Iowa Innovation Acceleration Fund
Series C (2020): $2M featuring OSF Ventures
Key Investors in Vida Diagnostics
OSF Ventures
OSF Ventures LLC is a venture capital firm operating within the Venture Capital & Private Equity sector, likely focusing on investments that drive innovation in healthcare or related technology sectors.
Iowa Seed Fund
Iowa Seed Fund II LLC is an investment entity that provides early-stage capital, suggesting a focus on nurturing emerging companies with high growth potential, particularly within the Iowa region.
Next Level Ventures
Next Level Ventures is an investment firm specializing in strategic funding from seed to growth stages, with a notable emphasis on fintech and supporting portfolio companies with operational and networking assistance.
What's next for Vida Diagnostics?
With its recent major enterprise-level funding, Vida Diagnostics is poised for accelerated growth and expanded market penetration. The company's trajectory suggests a strategic focus on further developing its data intelligence platform and broadening its clinical applications. Future investments will likely target enhancing its AI-driven analytics capabilities and forging deeper partnerships within the healthcare ecosystem. This capital will enable Vida Diagnostics to solidify its position as a leader in respiratory care technology, driving innovation and improving patient care on a larger scale.
See full Vida Diagnostics company page
